47th week of 2013 patent applcation highlights part 50 |
Patent application number | Title | Published |
20130310330 | METHOD FOR TREATING OBESITY - The present invention is directed to methods for treating obesity, reducing excessive body weight, treating an obesity-related condition, treating unwanted localized fat deposits, and treating areas of cellulite. The method comprises the steps of first identifying a subject in need thereof, and administering to the subject an effective amount of rhamnolipids. A pharmaceutical composition comprising rhamnolipids can be applied by any accepted mode of administration including oral, intranasal, subcutaneous, percutaneous, intravenous, or intracutaneous administration. | 2013-11-21 |
20130310331 | ANTIDIABETIC ENOLIC GLUCOSIDE OF PHENYLPYRUVIC ACID - There is provided an antidiabetic enolic glucoside of phenylpyruvic acid and derivatives thereof for use as medicaments, especially normoglycemic agents, i.e. for lowering blood glucose levels to normal levels in mammals that are obese, pre-diabetic or have diabetes, obesity and/or syndrome X. Hence the compounds of the present invention help to manage blood sugar levels, i.e. helping the body by balancing the blood sugar levels; helping to keep balanced blood glucose levels, particularly in humans with diabetes; aiding by enhancing the glucose uptake by the cells and by reducing sugar levels, thus improving or restoring the glucose tolerance; optimizing the glycemic response; normalizing the glucose tolerance. | 2013-11-21 |
20130310332 | MAPLE TREE-DERIVED PRODUCTS AND USES THEREOF - The present document describes a neutraceutical, cosmeceuticals, functional food, pharmaceutical, food ingredient, and non-food ingredient compositions comprising sugar maple extract, essential oil compositions comprising oil extracted from an | 2013-11-21 |
20130310333 | Modulators of Histone Methyltransferase, and Methods of Use Thereof - Disclosed are compounds, pharmaceutical compositions containing the compounds, and the uses of the compounds and compositions as modulators of histone methyltransferases, and for treating diseases influenced by modulation of histone methyltransferase activity. | 2013-11-21 |
20130310334 | 7-Deazapurine Modulators of Histone Methyltransferase, and Methods of Use Thereof - Disclosed are compounds, pharmaceutical compositions containing the compounds, uses of the compounds and compositions as modulators of histone methyltransferases, and methods for treating diseases influenced by modulation of histone methyltransferase activity. | 2013-11-21 |
20130310335 | PROLONGED RELEASE BIOADHESIVE THERAPEUTIC SYSTEMS - The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. Said bioadhesive therapeutic system comprises quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar. | 2013-11-21 |
20130310336 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES - A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided. | 2013-11-21 |
20130310337 | COMPOSITION AND METHOD TO ALLEVIATE JOINT PAIN USING A MIXTURE OF FISH OIL AND FISH OIL DERIVED, CHOLINE BASED, PHOSPHOLIPID BOUND FATTY ACID MIXTURE INCLUDING POLYUNSATURATED EPA AND DHA - Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form. | 2013-11-21 |
20130310338 | Glucans - The present invention relates to a glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×10 | 2013-11-21 |
20130310340 | METHOD OF TREATING MUSCULAR DEGRADATION - A method for treating muscular deterioration is disclosed. Also disclosed are embodiments of a compound, and compositions comprising the compound, for inhibiting muscular deterioriation, including atrophy, dystrophy, and cachexia, such as may result from ventilation. | 2013-11-21 |
20130310341 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses - The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications. | 2013-11-21 |
20130310342 | Aminopyrimidine Kinase Inhibitors - Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of CK1, CK1γ1, CK1γ2, CK1γ3, CK2, Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of CK1, CK1γ1, CK1γ2, CK1γ3, CK2, Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK/STAT pathway, the AKT pathway, and/or the mTOR pathway. | 2013-11-21 |
20130310343 | CRYSTALLINE FORM OF R)-3-(4-(2-(2-METHYLTETRAZOL-5-YL)PYRIDIN- 5-YL)-3-FLUOROPHENYL)-5-HYDROXYMETHYL OXAZOLIDIN-2-ONE DIHYDROGEN PHOSPHATE - A crystalline form of crystalline (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate, methods of making the crystalline form and pharmaceutical compositions comprising the crystalline form are useful antibiotics. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as | 2013-11-21 |
20130310344 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS - The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-X | 2013-11-21 |
20130310345 | Use of TRPA1 Antagonists to Prevent or Treat Infections Caused by Biological-Warfare Agents - Provided are methods for preventing and treating injuries caused by exposure to biological warfare agents. The methods include administering to a subject in need thereof an effective amount of a TRPA1 antagonist or a pharmaceutically acceptable salt thereof. In an embodiment the TRPA1 antagonist is selected from the group consisting of compounds of formula I | 2013-11-21 |
20130310346 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS WITH IRON CHELATORS - The present invention provides methods and compositions for treating or preventing bacterial infections, where a pharmaceutically acceptable iron chelator that reduces biological availability of iron for one or more strains of bacteria, such as VK28 or an analog or derivative thereof is administered to a patient in need of treatment. The method also provides methods and compositions where an iron chelator and an antibiotic are administered to a patient in need of treatment for a bacterial infection. | 2013-11-21 |
20130310347 | MULTI-MODALITY MOLECULAR IMAGING HIGH-THROUGHPUT ASSAY FOR IDENTIFYING HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS - High throughput methods for identifying novel inhibitors of Hsp90 chaperone protein folding are disclosed. The inhibitors so identified disrupt the binding of p23 to either Hsp90α or Hsp90β and have selective activity against the proliferation of cancer cells. In particular are provided embodiments of therapeutic compositions that comprise at least one inhibitor of an Hsp90 chaperone activity, the inhibitor being any of the compounds designated as CP1-CP19 as shown in FIGS. | 2013-11-21 |
20130310348 | QUINOLINE DERIVATIVES AND USES THEREOF - This disclosure provides a new class of compounds referred to as “reversed chloroquines” (RCQs), which are highly effective against CQ | 2013-11-21 |
20130310349 | GLYCERYL AND GLYCOL ACID COMPOUNDS - Disclosed is a method for moisturizing skin comprising topically applying to skin in need of moisturization a composition comprising a glyceryl di-salicylate compound having the following structure: | 2013-11-21 |
20130310350 | METHOD FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCERS AND COMPOSITIONS RELATED THERETO - Use of compounds disclosed herein, typically progesterone or analog or derivative thereof, in the treatment of central nervous system cancers, specifically neuroblastoma and glioblastoma is provided. The treatment offers a reduced toxicity as compared to the currently available chemotherapeutic agents. The progesterone may be administered alone or in combination with, or in conjunction with other therapeutic agents. | 2013-11-21 |
20130310351 | Treating Long QT Syndrome - This document relates to compounds useful for treating cardiac arrhythmias, for example, long QT syndrome. Also provided herein are methods and materials for using such compounds to shorten myocardial repolarization time in a patient. | 2013-11-21 |
20130310352 | DEXAMETHASONE COMBINATION THERAPY - The present invention relates to a method of treating multiple myeloma in a subject comprising administering to the subject an amount of (1) a compound of formula (I), as described herein, and/or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and an amount of (2) dexamethasone and/or a pharmaceutically acceptable salt, solvate, metabolite or racemate thereof, such that the subject is treated. In another aspect, provided herein is a method of treating multiple myeloma in a subject comprising administering to the subject an amount of (1) a compound of formula (I) and an amount of (2) dexamethasone, such that the subject is treated; pharmaceutical formulations comprising said combination for the treatment of multiple myelom; and compositions thereof. | 2013-11-21 |
20130310353 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME - Provided is a pharmaceutical composition comprising: (i) 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo-[2.2.2]octane or an enantiomer, mixture of enantiomers, or a racemate thereof, wherein an anion X | 2013-11-21 |
20130310354 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS - Combinations comprising (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease. | 2013-11-21 |
20130310355 | LOW TOXICITY TOPICAL ACTIVE AGENT DELIVERY SYSTEM - An active agent delivery composition is provided that allows topical delivery of active agents including vitamin A and its derivatives. A volatile vehicle serves as a coupler for an active agent and an organosiloxane carrier so as to allow full solubilization of active agents not normally miscible in silicones and providing a non-irritating, targeted evaporating composition. | 2013-11-21 |
20130310356 | METHOD FOR TREATING BRAIN CANCER - Methods and compositions for treating brain cancer are disclosed, including refractory brain cancer. | 2013-11-21 |
20130310357 | Azolyl Urea Compounds and Methods of Use Thereof - Provided herein are azolyl urea compounds for treatment of CSF-1R kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions. | 2013-11-21 |
20130310359 | NOVEL AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to novel azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2013-11-21 |
20130310360 | NOVEL OXIME AZETIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to novel oxime azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2013-11-21 |
20130310361 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS - The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or analplastic lymphoma kinase (ALK). | 2013-11-21 |
20130310362 | FUSED PYRIMIDINES - The present invention relates to compounds of formula (I), | 2013-11-21 |
20130310363 | IMIDAZOPYRIZINE SYK INHIBITORS - Certain imidazopyrazines of Formula (I): | 2013-11-21 |
20130310364 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. | 2013-11-21 |
20130310365 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 - The present invention comprises compounds of Formula I. | 2013-11-21 |
20130310366 | 5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF | 2013-11-21 |
20130310367 | METHOD OF ENHANCING PERFORMANCE IN BROILER CHICKENS - A method of enhancing the performance of chicken comprising administering zilpaterol to the chicken wherein the concentration of zilpaterol is from about 1 ppm to about 13 ppm and is administered every day for a period of about 7 to about 21 days. | 2013-11-21 |
20130310368 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF - The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) | 2013-11-21 |
20130310369 | SALTS OF LORCASERIN WITH OPTICALLY ACTIVE ACIDS - Salts of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine with optically active acids, and pharmaceutical compositions comprising them that are useful for, inter alia, weight management. | 2013-11-21 |
20130310370 | DRUG THERAPY FOR PREVENTING OR TREATING GLAUCOMA - There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (S)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma. | 2013-11-21 |
20130310371 | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexa- ne-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam - The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is an oxicam selected from the group consisting of meloxicam, piroxicam, tenoxicam, lornoxicam, droxicam and the physiologically acceptable salts thereof. | 2013-11-21 |
20130310372 | PHARMACEUTICAL TRANSDERMAL COMPOSITIONS AND METHOD FOR TREATING INFLAMMATION IN CATTLE - Novel transdermal preparations combining a non-steroidal anti-inflammatory drug (NSAID) selected from groups such as oxicams (for example, meloxicam), propionic acids (for example, ketoprofen) and anthranilic acids (for example, tolfenamic acid), are disclosed. Methods for using and administering such preparation in the treatment of inflammatory conditions in bovines are also disclosed. | 2013-11-21 |
20130310373 | PYRIMIDINE COMPOUND | 2013-11-21 |
20130310374 | Substituted Imidazoquinoline Derivatives - The present invention relates to substituted imidazo[4,5-c]quinoline derivatives of formula (I), wherein R | 2013-11-21 |
20130310375 | N-(HETERO)ARYL, 2-(HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS - The present invention relates to compositions and methods for modulating the Wnt signaling pathway. | 2013-11-21 |
20130310376 | 2-ARYL-4-QUINAZOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS - Provided is a compound of the formula I or a pharmaceutically acceptable salt, solvate or stereoisomer thereof: | 2013-11-21 |
20130310377 | NOVEL MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL - Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer. | 2013-11-21 |
20130310378 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS - The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). R | 2013-11-21 |
20130310379 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF - Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein. | 2013-11-21 |
20130310380 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE - Compounds are disclosed which modulate the α7 nicotinic acetyl choline receptor (nAChR), having the formula (I) wherein the variables are as specified in the description and claims. | 2013-11-21 |
20130310381 | SUBSTITUTED SODIUM-1H-PYRAZOLE-5-OLATE - The present application relates to sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate, to processes for its preparation, to its use for the treatment and/or prophylaxis of diseases and to its use for the preparation of medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing. | 2013-11-21 |
20130310382 | P53 ACTIVATING COMPOUNDS - The present invention relates to compounds which activate the p53 response, and find use in, for example, hyperproliferative diseases such as cancer treatment and potentially other diseases/conditions involving sirtuin function. | 2013-11-21 |
20130310383 | 1-ARYL -1-HYDROXY -2,3-DIAMINO-PROPYL AMIN ES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY - Compounds of the formula | 2013-11-21 |
20130310384 | Sulfonamide-Containing Compounds - This invention relates generally to the discovery of sulfonamide-containing compounds that are inhibitors of γ-secretase. | 2013-11-21 |
20130310385 | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexa- ne-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants - The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is an antidepressant. | 2013-11-21 |
20130310386 | METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION - Methods for treating eye diseases associated with inflammation and/or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof. | 2013-11-21 |
20130310387 | Monocyclic Heteroaryl Cycloalkyldiamine Derivatives - The present invention relates to monocyclic heteroaryl cycloalkyldiamine derivatives, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them. | 2013-11-21 |
20130310388 | Modulators of TNF-Alpha Signaling - The present invention provides compounds which are modulators of TNF-α signaling and methods of use thereof for treating a patient having a TNF-α mediated condition. The compounds can be represented by the following structural formulas: | 2013-11-21 |
20130310389 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS - The present invention is directed to methods of treating disorders mediated by Histamine H | 2013-11-21 |
20130310390 | COMPOSITION, SYNTHESIS, AND USE OF NEW SUBSTITUTED PYRAN AND PTERIN COMPOUNDS - The present invention relates to substituted pterin compounds, their synthesis and use. In particular, the present invention relates to a new precursor compound and its analogs for synthesizing a new substituted pterin compound and its analogs. These new compounds are particularly suitable for treating molybdenum cofactor deficiency. | 2013-11-21 |
20130310391 | 7-AZAINDOLE DERIVATIVES - Compounds of the formula (I) in which R, R | 2013-11-21 |
20130310392 | PHARMACEUTICAL FORMULATION FOR TOPICAL ADMINISTRATION COMPRISING B220 - A pharmaceutical composition for topical administration including 2,3-dimethyl-6-(N,N-dimethylaminoethyl)-6H-indolo-(2,3-b)quinoxaline (B-220) or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier. The composition is useful for the treatment of herpes virus infections of the skin or mucous membranes in a mammal subject. | 2013-11-21 |
20130310393 | SUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINE COMPOUNDS USEFUL AS CYP17 MODULATORS - Disclosed are heteroaryl compounds of Formula (I), (I), or pharmaceutically acceptable salts thereof, wherein Z is CH or N; W is CR | 2013-11-21 |
20130310394 | KINASE INHIBITORS - The present invention relates to compounds of Formula I | 2013-11-21 |
20130310395 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 - The present invention relates to compounds of formula (I): | 2013-11-21 |
20130310396 | THIAZOLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE - This invention provides deuterated thiazolidine derivatives and compositions comprising these compounds, which are useful agents for the treatment of hyperglycemia diseases or disorders, in particular diabetes mellitus. The disclosure also provides a method of treating hyperglycemia diseases or disorders, in particular diabetes mellitus, using these deuterated thiazolidine derivatives. | 2013-11-21 |
20130310397 | TERNARY MIXTURE FORMULATIONS - The invention relates to a novel free-flowing powder pharmaceutical formulation for the delivery of a poorly-water-soluble drug substance that increases the solubility and bioavailability of the poorly- water soluble drug substance, as well as to a method of making the free-flowing powder pharmaceutical formulation. The invention also relates to dispersed particles that disperse instantaneously from the free-flowing powder formulation when the formulation is added to water, aqueous solvent, or organic solvent, wherein the bulk distribution of the poorly-water soluble drug substance of the free-flowing powder formulation in the dispersed particles is uniform. Such dispersed particles increase the bioavailable surface area of the poorly water-soluble drug substance and facilitate the drug substance's dissolution. | 2013-11-21 |
20130310398 | Combination therapy for the treatment of diabetes and related conditions - Combinations of DPP-4 inhibitors with GPR119 agonists, as well as to the use of these combinations for treating and/or preventing metabolic diseases, particularly diabetes (especially type 2 diabetes mellitus) and conditions related thereto. | 2013-11-21 |
20130310399 | CHEMICAL COMPOUNDS - An insecticidal acaricidal and nematicidal composition of formula I | 2013-11-21 |
20130310400 | SPIRO AMINIC COMPOUNDS WITH NK1 ANTAGONIST ACTIVITY - The invention concerns a spiro-amino compound of Formula (I), wherein A is selected from a 5- or 6-membered aromatic ring and a 5- or 6-membered heteroaromatic ring containing 1 to 3 nitrogen atom; X is a substituent selected from the group consisting of (C | 2013-11-21 |
20130310401 | METHOD AND KITS FOR DETERMINING PLATELET SUSCEPTIBILITY TO ACTIVATION IN A PATIENT - The invention relates to methods and kits for determining platelet susceptibility to activation in a patient. More particularly, the present invention relates to a method for determining platelet susceptibility to activation in a patient, comprising a step consisting of measuring the level of GPVI dimers at the platelet surface in a blood sample obtained from said patient. | 2013-11-21 |
20130310402 | USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) - Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile. | 2013-11-21 |
20130310403 | Fluoro-homoneplanocin A and nucleoside derivatives, method for the synthesis thereof, and the pharmaceutical compositions comprising the same as an active component for treatment of cancer - The present invention relates to a fluoro-homoneplanocin A, its nucleoside derivative, and synthetic methods. The novel fluoro-homoneplanocin A and its nucleoside derivative in the present invention have an effect on cancer prevention or treatment, and therefore can be used as anticancer drugs. | 2013-11-21 |
20130310404 | INHIBITORS OF P75 RECEPTOR AND THEIR USES - Novel p75 receptor antagonist compounds and compositions and uses thereof for the prevention and treatment of p75-associated disorders, such as neurodegenerative diseases, are described. | 2013-11-21 |
20130310405 | SUBSTITUTED PYRIMIDO[1,2-B]INDAZOLES AND THEIR USE AS MODULATORS OF THE PI3K/AKT PATHWAY - Compounds of Formula (I), which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals. The compounds of formula (I) a: useful for the treatment of cancer. | 2013-11-21 |
20130310406 | MIR-193A-3P AND ASSOCIATED GENES PREDICT TUMORIGENESIS AND CHEMOTHERAPY OUTCOMES - The disclosure provides a correlation between the expression level of the miR-193a gene, which can be regulated by its methylation status, and both tumorigenesis of and the resistance of a cancer cell to a pyrimidine antimetabolite (5-FU) based chemotherapy. In addition to the methylation status and the expression of miR-193a, its downstream genes, such as E2F1, SRSF2, and apoptotic genes such as caspase 2, are also involved and can serve as useful markers for cancer therapy prognosis and for therapy selection. | 2013-11-21 |
20130310407 | COMBINATIONS COMPRISING MACITENTAN FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME - The invention relates to the use of macitentan in combination with a cytotoxic therapy agent (such as temozolomide or paclitaxel), with radiotherapy or with both a cytotoxic therapy agent and radiotherapy, in the treatment of malignant glioma, in particular glioblastoma multiforme. | 2013-11-21 |
20130310408 | Pesticidal Arylpyrrolidines - The invention is directed to arylpyrrolidines compounds which exhibit excellent insecticidal efficacy and which may be used as in the agrochemical field or in the vield of veterinary medicine. The compounds are represented by formula (I): | 2013-11-21 |
20130310409 | FORMS OF RIFAXIMIN AND USES THEREOF - Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them. | 2013-11-21 |
20130310410 | POLYMORPHOUS FORMS OF RIFAXIMIN, PROCESSES FOR THEIR PRODUCTION AND USE THEREOF IN THE MEDICINAL PREPARATIONS - Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin δ and rifaximin ε useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention. | 2013-11-21 |
20130310411 | NOVEL ACRIDINE DERIVATIVES - The present invention relates to novel acridine derivatives of formula (I), or pharmaceutically acceptable salts thereof, which are inhibitors of the telomerase enzyme function. These compounds are useful for the treatment cellular proliferation disorders, such as cancer. | 2013-11-21 |
20130310414 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CACHEXIA - A therapeutic or prophylactic agent for cachexia includes as an effective ingredient a compound having a specified morphinan skeleton represented by a compound of the following structure: | 2013-11-21 |
20130310415 | MORPHINAN COMPOUNDS - This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ | 2013-11-21 |
20130310416 | Methods and Compositions for Preventing or Treating Age-Related Diseases - The invention provides methods for treating or preventing an age-related disease, condition, or disorder comprising administering a therapeutically effective amount of an inhibitor of TOR to a patient in need thereof. The invention also provides pharmaceutical compositions and topical formulations for treating or preventing an age-related disease, condition, or disorder comprising an inhibitor of TOR and a pharmaceutically acceptable carrier. In particular, the invention provides methods, pharmaceutical compositions, and topical formulations comprising rapamycin or an analog of rapamycin. | 2013-11-21 |
20130310417 | Small Molecules For Endothelial Cell Activation - The present invention provides small molecules for endothelial cell activation and compositions thereof and methods of making and using the same. | 2013-11-21 |
20130310418 | Azaindazoles useful as inhibitors of kinases - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2013-11-21 |
20130310419 | PYRROLE DERIVATIVES USED AS MODULATORS OF ALPHA7 NACHR - The present invention is related to pyrrole derivatives of formula I as the modulators of nicotinic acetylcholine receptors particularly the α7 subtype. The invention includes pyrrole derivatives, analogues, their prodrugs, their isotopes, their metabolites, pharmaceutically acceptable salts, polymorphs, solvates, optical isomers, clathrates, co-crystals, combinations with suitable medicament and pharmaceutical compositions thereof. The present invention also includes process of preparation of the said compounds and intended use in therapy of them. Owing to the modulatory activity of the pyrrole derivatives on the nicotinic acetylcholine receptors, the invention finds application in the prophylaxis and therapy of disorders encompassing the involvement of cholinergic transmission in the central and peripheral nervous system. The invention relates to the ability of pyrrole derivatives to modulate the cholinergic transmission and efficacy of the endogenous neurotransmitter ACh thorough the nicotinic acetylcholine receptors particularly the α7 subtype. | 2013-11-21 |
20130310420 | STABLE FORMULATIONS OF PITAVASTATIN - Disclosed is a pharmaceutical composition comprising pitavastatin, or its salt or ester and MgO, of which the aqueous solution or dispersion has pH of from 10 to 10.8. The composition has good time-dependent stability and has no change in its outward appearance even after having been stored long. | 2013-11-21 |
20130310421 | TREATMENT OF AMYLOID BETA AMYLOIDOSIS - Provided is a method for the treatment and/or prevention of an amyloid beta amyloidosis in a subject comprising the step of administering to the subject an effective amount of a 5-lipoxygenase-activating protein (FLAP) antagonist. In preferred embodiments, the FLAP antagonist is MK-591, or a pharmaceutically acceptable salt thereof. Also provided is a method for decreasing or preventing the deposition of beta amyloid in the brain of a subject comprising the step of administering to a subject an effective amount of a FLAP antagonist. In preferred embodiments, the FLAP antagonist is MK-591, or a pharmaceutically acceptable salt thereof. | 2013-11-21 |
20130310423 | DITERPENOID DERIVATIVES ENDOWED OF BIOLOGICAL PROPERTIES - The present invention relates to new diterpenoid derivatives of formula (I), processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, urinary incontinence, asthma, or Alzheimer's disease and/or to prevent obstructive vascular lesions consequently to arteriotomy and/or angioplasty, and to prevent organ damage in hypertensive patients. | 2013-11-21 |
20130310424 | AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF - Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described. | 2013-11-21 |
20130310425 | NOVEL POLYMORPH FORMS OF (2S)-(4E)-N-METHYL-5-[3-(5-ISOPROPOXYPYRIDIN)YL]-4-PENTEN-2-AMINE - Polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate, and methods for their preparation, pharmaceutical composition containing said polymorph(s) and use, are disclosed. The polymorphs can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders. | 2013-11-21 |
20130310426 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 2013-11-21 |
20130310427 | INHIBITORS OF HCV NS5A PROTEIN - Antiviral compounds may be used to inhibit or reduce the activity of Hepatitis C virus (HCV), particularly HCV's NS5A protein. In these contexts, inhibition and reduction of activity of the NS5A protein refers to a lower level of the measured activity relative to a control experiment in which the cells or the subjects are not treated with the test compound. The inhibition or reduction in the measured activity is at least a 10% reduction or inhibition. The compounds and their isomeric forms and pharmaceutically acceptable salts thereof are useful in treating and preventing HCV infection alone or when used in combination with other compounds targeting viral or cellular elements or functions involved in the HCV lifecycle. | 2013-11-21 |
20130310428 | THERMO-STABLE, ARSENIC-FREE SYNERGISTIC BIOCIDE CONCENTRATE COMPOSITION FOR POLYMER MATRICES AND PROCESS FOR PREPARING SAME - A thermo-stable, arsenic-free synergistic biocide concentrate composition to afford enhanced antimicrobial properties to a polymer matrix comprising (i) a mixture of trihalomethyl-thio-phthalimide analogue and a second biocide; (ii) an antioxidant; (iii) a carrier; and (iv) optionally, one or more additives. The composition is capable of withstanding high processing temperatures up to about 250° C., substantially without thermal degradation of biocides and discoloration of the polymer matrix employed. | 2013-11-21 |
20130310429 | ITE for Cancer Intervention and Eradication - A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. The formulated drug can also be administered together with one or more of other cancer therapeutic agents. A maintenance dosing is provided after the subject is free of cancer to insure the cancer eradication. Subjects with cancers of prostate, liver, lung, ovarian, and breast are preferably accepted for treatment. | 2013-11-21 |
20130310430 | COMPOSITIONS AND METHODS OF USING (R)-PRAMIPEXOLE - Pharmaceutical compositions of (R)-pramipexole and methods and kits of using such compositions for the treatment of neurodegenerative diseases, or those related to mitochondrial dysfunction or increased oxidative stress are disclosed. | 2013-11-21 |
20130310431 | USES FOR SUBSTITUTED 2-AMINO-THIAZOLONES IN TREATING ALZHEIMER'S DISEASE - The invention provides 11-β-hydroxysteroid dehydrogenase type 1 enzyme (11βHSD1) inhibitors, such as a compound of the formula: (A), its hydroxy and keto metabolites, and pharmaceutically acceptable salts thereof, for treating cognitive disorders, including age-related cognitive disorders, such as Alzheimer's Disease. Also provided are methods and uses for inhibiting 11βHSD1 and for reducing the concentration or preventing the elevation of concentration of cortisol in the brain of a subject by administering the compound of the formula (A); its hydroxy and keto metabolites, and pharmaceutically acceptable salts thereof. | 2013-11-21 |
20130310432 | NOVEL THIAZOLIDIN-4-ONE-DERIVATIVES - The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4-one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents. | 2013-11-21 |
20130310433 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, or disorders. The invention also relates to processes for preparing compounds of the inventions. | 2013-11-21 |
20130310434 | Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4'9'-dihydro-3'H-spiro[cyclohexan- e-1,1'-pyrano[3,4,b]indol]-4-amine and a gabapentinoid - The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from gabapentinoids and the physiologically acceptable salts thereof. | 2013-11-21 |